vs
STANDARD BIOTOOLS INC.（LAB）与Zeo Energy Corp.（ZEO）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Zeo Energy Corp.的1.1倍（$19.6M vs $18.6M），Zeo Energy Corp.净利率更高（-10.8% vs -177.4%，领先166.6%），Zeo Energy Corp.同比增速更快（-0.4% vs -11.5%），Zeo Energy Corp.自由现金流更多（$2.3M vs $-23.1M），过去两年Zeo Energy Corp.的营收复合增速更高（-4.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
LAB vs ZEO — 直观对比
营收规模更大
LAB
是对方的1.1倍
$18.6M
营收增速更快
ZEO
高出11.0%
-11.5%
净利率更高
ZEO
高出166.6%
-177.4%
自由现金流更多
ZEO
多$25.4M
$-23.1M
两年增速更快
ZEO
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $18.6M |
| 净利润 | $-34.7M | $-2.0M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -11.8% |
| 净利率 | -177.4% | -10.8% |
| 营收同比 | -11.5% | -0.4% |
| 净利润同比 | -28.8% | -360.9% |
| 每股收益（稀释后） | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABZEO
| Q4 25 | — | $18.6M | ||
| Q3 25 | $19.6M | $23.9M | ||
| Q2 25 | $21.8M | $18.1M | ||
| Q1 25 | $40.8M | $8.8M | ||
| Q4 24 | — | $18.6M | ||
| Q3 24 | $22.1M | $19.7M | ||
| Q2 24 | $22.5M | $14.8M | ||
| Q1 24 | $45.5M | $20.1M |
净利润LABZEO
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $-34.7M | $-3.2M | ||
| Q2 25 | $-33.5M | $-2.4M | ||
| Q1 25 | $-26.0M | $-6.4M | ||
| Q4 24 | — | $-435.3K | ||
| Q3 24 | $-26.9M | $-424.3K | ||
| Q2 24 | $-45.7M | $-277.8K | ||
| Q1 24 | $-32.2M | $-1.5M |
毛利率LABZEO
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | 57.9% | ||
| Q2 25 | 48.8% | 59.8% | ||
| Q1 25 | 48.4% | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | 50.2% | ||
| Q2 24 | 46.1% | 52.3% | ||
| Q1 24 | 53.1% | — |
营业利润率LABZEO
| Q4 25 | — | -11.8% | ||
| Q3 25 | -168.5% | -8.3% | ||
| Q2 25 | -118.1% | -15.8% | ||
| Q1 25 | -80.8% | -153.8% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | -120.9% | -15.2% | ||
| Q2 24 | -134.5% | -18.0% | ||
| Q1 24 | -132.2% | -20.1% |
净利率LABZEO
| Q4 25 | — | -10.8% | ||
| Q3 25 | -177.4% | -13.5% | ||
| Q2 25 | -153.7% | -13.3% | ||
| Q1 25 | -63.8% | -72.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -122.0% | -2.2% | ||
| Q2 24 | -203.3% | -1.9% | ||
| Q1 24 | -70.6% | -7.6% |
每股收益（稀释后）LABZEO
| Q4 25 | — | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | $-0.48 | ||
| Q4 24 | — | $1.11 | ||
| Q3 24 | $-0.07 | $-0.08 | ||
| Q2 24 | $-0.12 | $0.03 | ||
| Q1 24 | $-0.27 | $-1.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $6.1M |
| 总债务越低越好 | — | $79.1K |
| 股东权益账面价值 | $399.7M | $5.3M |
| 总资产 | $539.6M | $56.9M |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资LABZEO
| Q4 25 | — | $6.1M | ||
| Q3 25 | $129.4M | $3.9M | ||
| Q2 25 | $158.6M | $68.7K | ||
| Q1 25 | $150.9M | $2.9M | ||
| Q4 24 | — | $5.6M | ||
| Q3 24 | $210.6M | $4.3M | ||
| Q2 24 | $269.8M | $5.3M | ||
| Q1 24 | $287.1M | — |
总债务LABZEO
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | $55.2M | $858.6K | ||
| Q2 24 | $55.1M | $1.6M | ||
| Q1 24 | $55.0M | $748.8K |
股东权益LABZEO
| Q4 25 | — | $5.3M | ||
| Q3 25 | $399.7M | $-1.7M | ||
| Q2 25 | $424.5M | $-59.4M | ||
| Q1 25 | $454.6M | $-23.1M | ||
| Q4 24 | — | $-88.9M | ||
| Q3 24 | $489.3M | $-39.3M | ||
| Q2 24 | $510.3M | $-53.0M | ||
| Q1 24 | $577.3M | $-173.0M |
总资产LABZEO
| Q4 25 | — | $56.9M | ||
| Q3 25 | $539.6M | $58.5M | ||
| Q2 25 | $557.0M | $46.2M | ||
| Q1 25 | $579.6M | $47.4M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | $681.5M | $47.1M | ||
| Q2 24 | $708.7M | $49.1M | ||
| Q1 24 | $777.7M | $50.1M |
负债/权益比LABZEO
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $2.4M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $2.3M |
| 自由现金流率自由现金流/营收 | -118.1% | 12.2% |
| 资本支出强度资本支出/营收 | 4.5% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-9.9M |
8季度趋势，按日历期对齐
经营现金流LABZEO
| Q4 25 | — | $2.4M | ||
| Q3 25 | $-22.2M | $-6.6M | ||
| Q2 25 | $-20.7M | $-2.3M | ||
| Q1 25 | $-30.3M | $-2.3M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | $-27.9M | $162.2K | ||
| Q2 24 | $-39.0M | $-2.2M | ||
| Q1 24 | $-62.5M | $-10.2M |
自由现金流LABZEO
| Q4 25 | — | $2.3M | ||
| Q3 25 | $-23.1M | $-6.8M | ||
| Q2 25 | $-22.6M | $-2.7M | ||
| Q1 25 | $-35.3M | $-2.6M | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | $-30.1M | $116.5K | ||
| Q2 24 | $-41.0M | $-2.3M | ||
| Q1 24 | $-63.3M | $-10.4M |
自由现金流率LABZEO
| Q4 25 | — | 12.2% | ||
| Q3 25 | -118.1% | -28.6% | ||
| Q2 25 | -103.6% | -15.0% | ||
| Q1 25 | -86.6% | -30.0% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | -136.4% | 0.6% | ||
| Q2 24 | -182.2% | -15.6% | ||
| Q1 24 | -138.9% | -51.5% |
资本支出强度LABZEO
| Q4 25 | — | 0.9% | ||
| Q3 25 | 4.5% | 1.0% | ||
| Q2 25 | 8.7% | 2.4% | ||
| Q1 25 | 12.4% | 4.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 10.2% | 0.2% | ||
| Q2 24 | 8.6% | 0.7% | ||
| Q1 24 | 1.7% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
